Phytomedicine : international journal of phytotherapy and phytopharmacology · 2026
Chelerythrine and chelidonine synergistically target the adenosine pathway to improve anti-PD-L1 immunotherapy efficacy in lung cancer.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhu Jinglin, Huang Ruifei, Huang Chao, Yan Jiangna, Zhang Yuru, Xiao Yue, Yang Ruijie, Liu Zhenni, Guan Haixia, Zhang Wen, Li Liang, Xiao Zhengtao, Xiao Wei, Zheng Chunli
Аннотация
BACKGROUND: Despite the success of immune checkpoint blockade in advanced cancer, non-redundant immunosuppressive mechanisms within the tumor microenvironment (TME) limit its effectiveness in many patients. Extracellular adenosine (eADO) signaling is a major contributor to immunosuppression, and inhibitors of eADO production or signaling have entered clinical trials as monotherapies or in combination with anti-PD-L1 therapy.
PURPOSE: We aimed to identify potent compounds from Chelidonium majus L. (C. majus) that target eADO production or signaling pathway and thereby improve the efficacy of anti-PD-L1 immunotherapy in lung cancer.
METHODS: A systems pharmacology platform was used to screen compounds from C. majus for potential antitumor activity. Synergistic interactions among the candidate compounds were evaluated using the Chou-Talalay method. The ability of chelerythrine and chelidonine (CC) to enhance anti-PD-L1 efficacy was evaluated in a syngeneic Lewis lung carcinoma (LLC) mouse model. ELISA, quantitative real-time PCR and Western blotting were used to assess eADO production and CD39/CD73-axis signaling in the CC-treated TME. Flow cytometry, Transwell co-culture assays and ELISA were used to evaluate immunomodulatory effects of CC on CD8+ T cells.
RESULTS: We investigated whether chelerythrine and chelidonine combined at a 1:1 concentration ratio (CC), two alkaloids derived from C. majus, inhibit eADO production and signaling through the CD39/CD73 axis and thereby enhance CD8+ T-cell responses in LLC-bearing mice. Computational modeling predicted favorable antitumor properties for CC, which were subsequently validated in vitro and in vivo. Mechanistically, CC significantly reduced CD39 and CD73 expression and alleviated eADO-mediated immunosuppression in the TME. CC also enhanced antitumor CD8+ T-cell immunity in LLC-bearing mice by increasing intratumoral infiltration and cytotoxic function. Furthermore, CC improved the therapeutic efficacy of anti-PD-L1 treatment in established tumors.
CONCLUSIONS: This study demonstrates that CC synergistically targets the eADO pathway and improves the efficacy of anti-PD-L1 immunotherapy through the CD39/CD73/A2AR axis in lung cancer model. These findings provide a scientific rationale for developing adenosine-targeted combination strategies with immune checkpoint blockade (ICB).
PURPOSE: We aimed to identify potent compounds from Chelidonium majus L. (C. majus) that target eADO production or signaling pathway and thereby improve the efficacy of anti-PD-L1 immunotherapy in lung cancer.
METHODS: A systems pharmacology platform was used to screen compounds from C. majus for potential antitumor activity. Synergistic interactions among the candidate compounds were evaluated using the Chou-Talalay method. The ability of chelerythrine and chelidonine (CC) to enhance anti-PD-L1 efficacy was evaluated in a syngeneic Lewis lung carcinoma (LLC) mouse model. ELISA, quantitative real-time PCR and Western blotting were used to assess eADO production and CD39/CD73-axis signaling in the CC-treated TME. Flow cytometry, Transwell co-culture assays and ELISA were used to evaluate immunomodulatory effects of CC on CD8+ T cells.
RESULTS: We investigated whether chelerythrine and chelidonine combined at a 1:1 concentration ratio (CC), two alkaloids derived from C. majus, inhibit eADO production and signaling through the CD39/CD73 axis and thereby enhance CD8+ T-cell responses in LLC-bearing mice. Computational modeling predicted favorable antitumor properties for CC, which were subsequently validated in vitro and in vivo. Mechanistically, CC significantly reduced CD39 and CD73 expression and alleviated eADO-mediated immunosuppression in the TME. CC also enhanced antitumor CD8+ T-cell immunity in LLC-bearing mice by increasing intratumoral infiltration and cytotoxic function. Furthermore, CC improved the therapeutic efficacy of anti-PD-L1 treatment in established tumors.
CONCLUSIONS: This study demonstrates that CC synergistically targets the eADO pathway and improves the efficacy of anti-PD-L1 immunotherapy through the CD39/CD73/A2AR axis in lung cancer model. These findings provide a scientific rationale for developing adenosine-targeted combination strategies with immune checkpoint blockade (ICB).